Hepatocelluar Carcinoma Risk in Advanced Fibrosis After Sustained Virologic Response: When Can We Safely Stop Hepatocellular Carcinoma Surveillance?

Detalles Bibliográficos
Autores principales: Enomoto, Masaru, Vutien, Philip, Kawada, Norifumi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Editorial
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8870040/
https://www.ncbi.nlm.nih.gov/pubmed/35202513
http://dx.doi.org/10.1002/hep4.1864
_version_ 1784656641216479232
author Enomoto, Masaru
Vutien, Philip
Kawada, Norifumi
author_facet Enomoto, Masaru
Vutien, Philip
Kawada, Norifumi
author_sort Enomoto, Masaru
collection PubMed
description
format Online
Article
Text
id pubmed-8870040
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-88700402022-02-28 Hepatocelluar Carcinoma Risk in Advanced Fibrosis After Sustained Virologic Response: When Can We Safely Stop Hepatocellular Carcinoma Surveillance? Enomoto, Masaru Vutien, Philip Kawada, Norifumi Hepatol Commun Editorial John Wiley and Sons Inc. 2022-02-24 /pmc/articles/PMC8870040/ /pubmed/35202513 http://dx.doi.org/10.1002/hep4.1864 Text en © 2021 The Authors. Hepatology Communications published by Wiley Periodicals, Inc., on behalf of the American Association for the Study of Liver Diseases. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle Editorial
Enomoto, Masaru
Vutien, Philip
Kawada, Norifumi
Hepatocelluar Carcinoma Risk in Advanced Fibrosis After Sustained Virologic Response: When Can We Safely Stop Hepatocellular Carcinoma Surveillance?
title Hepatocelluar Carcinoma Risk in Advanced Fibrosis After Sustained Virologic Response: When Can We Safely Stop Hepatocellular Carcinoma Surveillance?
title_full Hepatocelluar Carcinoma Risk in Advanced Fibrosis After Sustained Virologic Response: When Can We Safely Stop Hepatocellular Carcinoma Surveillance?
title_fullStr Hepatocelluar Carcinoma Risk in Advanced Fibrosis After Sustained Virologic Response: When Can We Safely Stop Hepatocellular Carcinoma Surveillance?
title_full_unstemmed Hepatocelluar Carcinoma Risk in Advanced Fibrosis After Sustained Virologic Response: When Can We Safely Stop Hepatocellular Carcinoma Surveillance?
title_short Hepatocelluar Carcinoma Risk in Advanced Fibrosis After Sustained Virologic Response: When Can We Safely Stop Hepatocellular Carcinoma Surveillance?
title_sort hepatocelluar carcinoma risk in advanced fibrosis after sustained virologic response: when can we safely stop hepatocellular carcinoma surveillance?
topic Editorial
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8870040/
https://www.ncbi.nlm.nih.gov/pubmed/35202513
http://dx.doi.org/10.1002/hep4.1864
work_keys_str_mv AT enomotomasaru hepatocelluarcarcinomariskinadvancedfibrosisaftersustainedvirologicresponsewhencanwesafelystophepatocellularcarcinomasurveillance
AT vutienphilip hepatocelluarcarcinomariskinadvancedfibrosisaftersustainedvirologicresponsewhencanwesafelystophepatocellularcarcinomasurveillance
AT kawadanorifumi hepatocelluarcarcinomariskinadvancedfibrosisaftersustainedvirologicresponsewhencanwesafelystophepatocellularcarcinomasurveillance

Ejemplares similares